Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Êîñìåòîëîãèÿ-äåðìàòîëîãèÿ > Ãåðïåñ - äèàãíîñòèêà è ëå÷åíèå

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #16  
Ñòàðûé 17.11.2003, 13:56
Àâàòàð äëÿ YuriTop
YuriTop YuriTop âíå ôîðóìà
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.12.2002
Ãîðîä: Yekaterinburg
Ñîîáùåíèé: 808
YuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Áëàãîäàðþ ãîñïîäèíà Çàéöåâà. Ññûëêà ïî ìîåìó î÷åíü ñâîåâðåìåííàÿ è âàæíàÿ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #17  
Ñòàðûé 17.11.2003, 14:24
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad íà ôîðóìå
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,855
Ïîáëàãîäàðèëè 33,441 ðàç(à) çà 31,784 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûå êîëëåãè Þðèé è Â.Çàéöåâ!

Ñóùåñòâóþò 2 ñîñòîÿíèÿ, îòëè÷àþùèõñÿ äðóã îò äðóãà:

1) äåôèöèò æåëåçà è âîñïðèèì÷èâîñòü îðãàíèçìà ê èíôåêöèÿì íà ýòîì ôîíå (âèðóñíûì, áàêòåðèàëüíûì, ãðèáêîâûì);
2) íàðóøåíèå îáìåíà æåëåçà, ýðèòðîïîýçà íà ôîíå îñòðîôàçîâîãî ïðîöåññà: èíôåêöèè, îïåðàòèâíîãî âìåøàòåëüñòâà, îïóõîëè è òä.

Íå ñîãëàøóñü â Âàìè, Þðèé, âîò ïî êàêîìó âîïðîñó:
"Òàê ÷òî ïðåïàðàòû æåëåçà ìîãóò âûçâàòü òîëüêî äàëüíåéøåå ïîääåðæàíèå èíôåêöèè."

Êðîìå âûøåóêàçàííîãî îò 26.06. èññëåäîâàíèÿ, ïîêàçûâàþùåãî ñíèæåíèå ãåðïåtè÷åñêèõ âûñûïàíèé íà ôîíå êîððåêöèè ñóùåñòâóþùåãî æåëåçîäåôèöèòà, ñóùåñòâóþò èññëåäîâàíèÿ, êîãäà êîððåêöèÿ æåëåçîäåôèöèòà ïîìîãàåò èçëå÷åíèþ îò ôóðóíêóëåçà è êàíäèäîçà êîæè è ñëèçèñòûõ.

Ïîýòîìó, "...äîêòîðàì ñëåäóåò ëå÷èòü ïðàâèëüíî äèàãíîñòèðîâàííûé ÆÄ áåç ñòðàõà àããðàâàöèè èíôåêöèè..."

Èç Best Pract Res Clin Haematol. 2002 Jun;15(2):411-26.

Iron and infection: competition between host and microbes for a precious element.

Marx JJ.

Eijkman-Winkler Institute for Microbiology, Infectious Diseases and Inflammation, University Medical Centre Utrecht, G04.614, PO Box 85500, 3508 GA Utrecht, The Netherlands


Î âèðóñàõ ãåïàòèòà è ÂÈ×: â îáîèõ ñëó÷àÿõ ñìåðòíîñòü/ïðîãðåññèðîâàíèå çàáîëåâàíèÿ îòìå÷àëèñü ïðè ÏÎÂÛØÅÍÍÛÕ ñîäåðæàíèÿõ æåëåçà â ïå÷åíè/òêàíÿõ/ÊÌ.

Åñëè èíòåðåñíî äèñêóòèðîâàòü/ïðîäîëæàòü îáùåíèå íà òåìó ÷òî ïðîèñõîäèò ñ æåëåçîì ïðè îñòðîôàçîâîì ïðîöåññå è êàê ðàçâèâàåòñÿ àíåìèÿ "âîñïàëåíèÿ" (áûâøàÿ àíåìèÿ õðîíè÷åñêèõ çàáîëåâàíèé), òî ìîæåì ïðîäîëæèòü...
Îòâåòèòü ñ öèòèðîâàíèåì
  #18  
Ñòàðûé 17.11.2003, 22:14
Àâàòàð äëÿ YuriTop
YuriTop YuriTop âíå ôîðóìà
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.12.2002
Ãîðîä: Yekaterinburg
Ñîîáùåíèé: 808
YuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
íå ñîìíåâàþñü âîïðîñ äèñêóòàáåëüíûé, íî! Êàê âðà÷ èíôåêöèîíèñò è èììóíîëîã ñàì íåîäíîêðàòíî íàáëþäàë ïðîëîíãèðîâàíèå ãåðïåòè÷åñêîãî ïðîöåññà ó áåðåìåííûõ, êîòîðûì íàçíà÷àëè â ïðåïàðàòû æåëåçà. Ýòî êàñàåòñÿ è HSV1-2 è CMV.
Êðîìå òîãî çäåñü ìû ñòàëêèâàåìñÿ ñ ðàñïðîñòðàíåííîé ìåäèöèíñêîé äèëåììîé -÷òî ïåðâè÷íî à ÷òî âòîðè÷íî.
Êñòàòè ïðè÷èí àíåìèè ò.å æåäåçîäåôèöèòà ãîðàçäî áîëüøå ÷åì äâå.
Ìíå êàæåòñÿ âû íåâíèìàòåëüíî ïðî÷ëè ñòàòüþ íà êîòîðóþ ññûëàëñÿ ã-í Çàéöåâ -öèòàòà "
Ïðåäøåñòâóþùèå ñîîáùåíèÿ ñâèäåòåëüñòâîâàëè, ÷òî ñíèæåíèå êîíöåíòðàöèè ñûâîðîòî÷íîãî æåëåçà ìîæåò óëó÷øàòü ãèñòîëîãè÷åñêèé è âèðóñîëîãè÷åñêèé îòâåò íà òåðàïèþ èíòåðôåðîíîì. Îäíàêî îñòàâàëîñü íåÿñíûì, ïðèâîäèò ëè ñíèæåíèå êîíöåíòðàöèè æåëåçà ê óëó÷øåíèþ îòäàëåííûõ ðåçóëüòàòîâ, êîãäà ïðèìåíÿåòñÿ áîëåå äëèòåëüíûé êóðñ òåðàïèè èëè áîëåå âûñîêèå äîçû èíòåðôåðîíà. Am J Gastroenterol 2002; 97: 1204-10
" îáðàòèòå âíèìàíèå çäåñü ðå÷ü èäåò èìåííî î ñûâîðîòî÷íîì æåëåçå, õîòÿ è âíóòðèòêàíåâîå æåëåçî áåçóñëîâíî èãðàåò ñâîþ ðîëü.
Îòâåòèòü ñ öèòèðîâàíèåì
  #19  
Ñòàðûé 18.11.2003, 10:16
AlexT AlexT âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 12.06.2003
Ãîðîä: Êðèâîé Ðîã
Ñîîáùåíèé: 861
Ïîáëàãîäàðèëè 64 ðàç(à) çà 61 ñîîáùåíèé
AlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
À êàê èìåííî âû íàáëþäàëè ïðîëîíãèðîâàíèå ÖÌÂ-èíôåêöèè ó áåðåìåííûõ?
Îòâåòèòü ñ öèòèðîâàíèåì
  #20  
Ñòàðûé 18.11.2003, 11:15
Àâàòàð äëÿ YuriTop
YuriTop YuriTop âíå ôîðóìà
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.12.2002
Ãîðîä: Yekaterinburg
Ñîîáùåíèé: 808
YuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Íåñìîòðÿ íà ïðîâîäèìóþ òåðàïèþ âûäåëåíèå DNA CMV ôèêñèðîâàëîñü â ðåàêöèè ÏÖÐ
Îòâåòèòü ñ öèòèðîâàíèåì
  #21  
Ñòàðûé 18.11.2003, 12:12
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad íà ôîðóìå
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,855
Ïîáëàãîäàðèëè 33,441 ðàç(à) çà 31,784 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Þðèé!

Äàâàéòå äåòàëüíî ðàçáèðàòüñÿ: ñ êàêîé öåëüþ áûëî íàçíà÷åíî æåëåçî ó áåðåìåííûõ - ñ ïðîôèëàêòè÷åñêîé - ïðåäóïðåæäåíèå æåëåçîäåôèöèòà ïðè ïðåîáëàäàíèè ïîòðåáíîñòè îðãàíèçìà íàä âîçìîæíîñòüþ âñàñûâàíèÿ (îäíà èç ãðóïï ïðè÷èí æåëåçîäåôèöèòà, äðóãàÿ - èçáûòî÷íûå ïîòåðè, òðåòüÿ - íàðóøåíèå ïîñòóïëåíèÿ), à áûë ëè ó íèõ æåëåçîäåôèöèò èçíà÷àëüíî, åñëè íåò - òî âïîëíå âåðîÿòíûì ìîãëî áûòü óõóäøåíèå òå÷åíèÿ èíô. ïðîöåññà.

Äàëåå, â îðèãèíàëüíûõ òåçèñàõ äàííîé ñòàòüè âîîáùå íå óïîìèíàåòñÿ ñûâîðîòî÷íîå æåëåçî:

...METHODS: One hundred fourteen hepatitis C virus (HCV) RNA positive patients with hepatic iron concentrations of > or =700 microg/g dry wt (men) and > or =500 microg/g dry wt (women)...

...Patients with hepatic iron concentration of < or = 1100 microg/g dry wt had a trend toward a higher rate of virological sustained response...

È ïðåäøåñòâóþùèå ñòàòüè òàêæå îöåíèâàëè íå êîëåáàíèÿ æåëåçà â ñûâîðîòêå...

Î ïåðâè÷íîì è âòîðè÷íîì: íàãëÿäíûé ïðèìåð - îáèëüíî ìåíñòðóèðóþùàÿ æåíùèíà /ëþáîé ÷åëîâåê - ÷àñòûé äîíîð èëè ñ íàëè÷èåì ïîñòîÿííî ïîäêðàâëèâàþùåãî ãåìîððîÿ/ çàáîëåë/à ãåíåðàëèçîâàííûì èíôåêöèîííûì ïðîöåññîì - ñäåëàëè àíàëèç êðîâè - ÆÄ àíåìèÿ. ×åì îíà âûçâàíà, à èíôåêöèîííûé ïðîöåññ óñîãèáëÿåò åå èëè íåò?

Ëþáîé äëèòåëüíûé èíôåêöèîííûé ïðîöåññ (ÑÏÈÄ, òóáåðêóëåç áåç êðîâîõàðêàíüÿ) - àíàëèç êðîâè - â íåì àíåìèÿ è íèçêîå æåëåçî - ýòî ÷òî ÆÄ àíåìèÿ è åå íóæíî ëå÷èòü ïð-òàìè æåëåçà?

Êðîâîïóñêàíèå ó âûøåóêàçàííûõ ïàöèåíòîâ è ó ïàöèåíòîâ ñ ýðèòðåìèåé/àáñóëþòíûì ýðèòðîöèòîçîì äåëàåòñÿ ñ îäíîé öåëüþ? Ïî÷åìó ïîñëåäíèì íàçíà÷àþòñÿ ïð-òû æåëåçà à ïåðâûì íåò? Ïî÷åìó ãåìîñèäåðîç/ãåìîõðîìàòîç âñòðå÷àåòñÿ ó ìóæ÷èí â ëþáîì âîçðàñòå, à ó æåíùèõ ïîñëå ìåíîïàóçû?

Èçâèíèòå çà âîïðîñèòåëüíûé òîí, íî êîãäà èùåøü îòâåò íà âîïðîñ "À çà÷åì ýòî ÿ äåëàþ â äàííîé êëèí. ñèòóàöèè?" âìåñòî "Äà íàì òàê â óíèâåðñèòåòå/ÊÏÊ ãîâîðèëè...", òî âñå ïðîÿñíÿåòñÿ...
Îòâåòèòü ñ öèòèðîâàíèåì
  #22  
Ñòàðûé 18.11.2003, 14:54
Àâàòàð äëÿ YuriTop
YuriTop YuriTop âíå ôîðóìà
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.12.2002
Ãîðîä: Yekaterinburg
Ñîîáùåíèé: 808
YuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Dr.VAD êîììåíòàðèé èñ÷åðïûâàþùèé, íî äàííàÿ äèñêóññèÿ âûõîäèò çà ðàìêè òåìû. ß õî÷ó àêöåíòèðîâàòü âíèìàíèå âîò íà êàêèõ ôàêòàõ:
1. Èçáûòîê Fe èñïîëüçóåòñÿ âèðóñîì äëÿ ñâîåé ðåïëèêàöèè
2. ñëó÷àå íàëè÷èÿ àêòèâíîé âèðóñíîé èíôåêöèè ó áåðåìåííîé íóæíî ëå÷èòü îñíîâíîå çàáîëåâàíèå.
3. Èçáûòîê Fe ïðèíèìàåìûé áåðåìåííîé ìîæåò ïîääåðæèâàòü ðåïëèêàöèþ âèðóñà.
Ýòî âîâñå íå çíà÷èò, ÷òî ÿ ïðîòèâ êîððåêöèè äåôèöèòà Fe íî íåîáõîäèìî ó÷èòûâàòü âñå ôàêòîðû âûçâàâøèå åãî äåôèöèò.

Äà êñòàòè, ôðàçà"Äà íàì òàê â óíèâåðñèòåòå/ÊÏÊ ãîâîðèëè...", ìåíÿ íå ñîâñåì êàñàåòñÿ ò.ê. íåäàâíî çàêîí÷èë äèññåðòàöèþ (ñêîðî çàùèòà) íà òåìó HCV è CMV ó áåðåìåííûõ è íîâîðîæäåííûõ è ïðåäìåò ñåé ìíå õîðîøî çíàêîì.
Êñòàòè ó íàñ â ÓÃÌÀ ñåé÷àñ â ðàáîòå íàñêîëüêî èññëåäîâàíèé êàê ðàç íà ýòó òåìó (àíåìèÿ è âèðóñíàÿ èíôåêöèÿ ó áåðåìåííûõ)
Îòâåòèòü ñ öèòèðîâàíèåì
  #23  
Ñòàðûé 18.11.2003, 15:58
AlexT AlexT âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 12.06.2003
Ãîðîä: Êðèâîé Ðîã
Ñîîáùåíèé: 861
Ïîáëàãîäàðèëè 64 ðàç(à) çà 61 ñîîáùåíèé
AlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Îïóáëèêîâàíî: YuriTop
Íåñìîòðÿ íà ïðîâîäèìóþ òåðàïèþ âûäåëåíèå DNA CMV ôèêñèðîâàëîñü â ðåàêöèè ÏÖÐ
À â êàêîì áèîìàòåðèàëå âûäåëÿëàñü ÄÍÊ ÖÌÂ?.
Îòâåòèòü ñ öèòèðîâàíèåì
  #24  
Ñòàðûé 18.11.2003, 16:40
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad íà ôîðóìå
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,855
Ïîáëàãîäàðèëè 33,441 ðàç(à) çà 31,784 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Þðèé!

Ñîãëàñåí ïî áîëüøèíñòâó ìîìåíòîâ, íî ïîçâîëüòå âûñêàçàòü äîïîëíèòåëüíûå ñîîáðàæåíèÿ:

âèðóñû, áàêòåðèîäû, áàêòåðèè, ïðîñòåéøèå âñåãäà íàéäóò ñïîñîá ïîëó÷åíèÿ æåëåçà â îðãàíèçìå õîçÿèíà âíå çàâèñèìîñòè îò òîãî, åñòü æåëåçîäåôèöèòíàÿ àíåìèÿ, íîðìàëüíûé æëåëåçíûé ñòàòóñ èëè åãî èçáûòîê. Âîò íàïð. îáüÿñíåíèÿ "æåëåçíûõ" âçàèìîîòíîøåíèé ìåæäó õîçÿèíîì è ÂÈ×:

...in-vitro HIV infection is associated with changes in iron metabolism, and an iron-mediated oxidative stress is likely to contribute to viral cytopathogenicity. Furthermore, it is interesting to point out that the interaction between iron and HIV may be reciprocal, since viruses with a life-cycle involving a DNA phase require chelatable iron for optimum replication...

Èç Cell Biochem Funct. 1999 Dec;17(4):279-87.
Iron metabolism and HIV infection: reciprocal interactions with potentially harmful consequences?
Savarino A, Pescarmona GP, Boelaert JR.

Ëè÷íî ìíå êàê âðà÷ó (äà äóìàþ è Âàì êàê èíôåêöèîíèñòó) ãîðàçäî âàæíåå ïî÷åìó çàùèòíûå ñèëû îäíîãî ïàöèåíòà íå ñïîñîáíû ýëèìèíèðîâàòü ðàçìíîæàþùèéñÿ âèðóñ, è ïî÷åìó ó îäíèõ öèðêóëèðóþùèé ðàçìíîæàþùèéñÿ âèðóñ âûçûâàåò ïîâðåæäåíèå òêàíåé (áîëåçíü), à ó äðóãèõ - íåò. Âîò çäåñü áû ìîæíî áûëî çàäóìàòüñÿ / ïðåäïîëîæèòü ðîëü æåëåçà:

Íàïð. âîò êàêèå èììóííûå íàðóøåíèÿ ìîæíî îáíàðóæèòü:

Cellular immunity is often altered in iron-deficient humans and in murine species.

Humoral immune responses seem far less affected in iron-deficient humans than is cellular immunity, but is impaired in iron-deficient animals. Results on complement are scarce and controversial.

There is almost no perturbation of phagocytosis but bactericidal activity is decreased in most studies on iron-deficient subjects.

Natural Killer activity is decreased in iron-deficient mice. Iron deficiency also affects lymphokine production in mice and rats.


Èç Comp Biochem Physiol A. 1989;94(1):11-9.

Iron status, immune capacity and resistance to infections.

Dhur A, Galan P, Hercberg S.

Òå, ïî ìîåìó ìíåíèþ, äîñòàòî÷íî îñíîâàòåëüíûé áàçèñ äëÿ ïîâûøåíèÿ âîñïðèèì÷èâîñòè ê èíôåêöèÿì.

Î íàêîïëåíèè æåëåçà è ðàçìíîæåíèè âèðóñà: íåïëîõî èçó÷åí ìàòåðèàë ïî HCV, oêàçûâàåòñÿ âûçûâàíèå æåëåçîäåôèöèòà ó ïàöèåíòîâ ñ ãåïàòèòîì Ñ íå îòðàæàåòñÿ íà êîëè÷åñòâåííîì ñíèæåíèè âèðèîíîâ â êðîâè à íà óìåíüøåíèè ïîâðåæäåíèÿ ïå÷åíî÷íûõ êëåòîê, òå ãðóáî ãîâîðÿ æèçíåäåÿòåëüíîñòü ãåïàòîòðîïíîãî âèðóñà ïëþñ íàëè÷èå èçáûòêà æåëåçà â êëåòêàõ ïå÷åíè âåäåò ê âîñïàëåíèþ (ãåïàòèò) - ôèáðîçèðîâàíèþ (öèððîç) - îçëîêà÷åñòâëåíèþ (ïå÷åíî÷íî-êëåòî÷íûé ðàê). Òåïåðü âíèìàíèå: íàëè÷èå ãåíîâ ïîâûøåííîãî âñàñûâàíèÿ æåëåçà âåäåò ê íàêîïëåíèþ æåëåçà â ïå÷åíè (ãåìîõðîìàòîç), ÷òî ïðèâîäèò ê öèððîçó è ïå÷åíî÷íî-êëåòî÷íîìó ðàêó:

Hepatocellular carcinoma (HCC) is the most common hepatic malignancy worldwide. The primary risk factor for the development of HCC is cirrhosis. Even patients without cirrhosis who develop HCC are typically found to have some underlying hepatic abnormality, such as steatohepatitis or chronic viral hepatitis. Although cirrhosis of any cause increases the risk of developing HCC, cirrhosis associated with chronic hepatitis B or C virus infection or hemochromatosis carries the greatest risk...

Äðóãèå íåïðèÿòíûå ïîñëåäñòâèÿ èçáûòêà ïîñòóïëåíèÿ æåëåçà â îðãàíèçì:

...Iron enhances the pathogenicity of microorganisms, adversely affects the function of macrophages and lymphocytes, and enhances fibrogenic pathways, all of which may increase hepatic injury due to iron itself or to iron and other factors. Iron may also be a co-carcinogen or promoter of hepatocellular carcinoma, even in patients without HC or cirrhosis...

Ïîäâîäÿ èòîã, ìîæíî çàêëþ÷èòü ñëåäóþùåå:

ïðåæäå, ÷åì íàçíà÷àòü ïð-òû æåëåçà, íóæåí óâåðåííûé (êëèí. è ëàá.) áàçèñ äëÿ åãî íàçíà÷åíèÿ: íàëè÷èå êàê ìèíèìóì òêàíåâîãî æåëåçîäåôèöèòà; ïðè íàëè÷èè êîìáèíèðîâàííîé àíåìèè ëó÷øå âîçäåéñòâîâàòü íà îñíîâíûå ïàòîãåíåòè÷åñêèå çâåíüÿ äàííîãî ïðîñåññà,
Íàëè÷èå òðàíçèòîðíîé èíôåêöèè â îðãàíèçìå íå ïîâîä äëÿ íåëå÷åíèÿ ÆÄÀ, íî ëó÷øå ñíà÷àëà ïîïûòàòüñÿ èçáàâèòü åãî îò èíôåêöèè. Ïðè íåêîòîðûõ èíôåêöèîííûõ ðåöèäèâèðóþùèõ ïðîöåññàõ äîáèòüñÿ áîëåå ñòîéêîé ðåìèññèè ìîæíî, îòêîððåêòèðîâàâ ñîïóòñòâóþùèé æåëåçîäåôèöèò.
Îòâåòèòü ñ öèòèðîâàíèåì
  #25  
Ñòàðûé 18.11.2003, 21:31
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Óâàæàåìûé Dr.VAD!
ß íå ñîáèðàëñÿ ïðîäîëæàòü ó÷àñòâîâàòü â ýòîé äèñêóññèè, ò.ê. íå ÿâëÿþñü ñïåöèàëèñòîì ïî ðàçáèðàåìûì âîïðîñàì. Ìîé íàñòîÿùèé ïîñò ñâÿçàí ëèøü ñ òåì, ÷òî, ïî ìîåìó ìíåíèþ, Âû íåòî÷íî èíòåðïðåòèðóåòå âûâîäû ñòàòüè, ññûëêó íà êîòîðóþ ÿ çäåñü ïðèâîäèë.
Ïîâåðòè, åñëè ýòà ðàáîòà áûëà áû ïîñâÿùåíà äîêàçàòåëüñòâàì, ÷òî «ëèøíåå æåëåçî» ýòî ïëîõî, ÿ áû íå ñòàë îáðàùàòü íà íå¸ Âàøå âíèìàíèå.
Âû ïèøèòå: â îðèãèíàëüíûõ òåçèñàõ äàííîé ñòàòüè âîîáùå íå óïîìèíàåòñÿ ñûâîðîòî÷íîå æåëåçî.
Ïðèâîæó ýòè òåçèñû ïîëíîñòüþ:
Am J Gastroenterol. 2002 May;97(5):1204-10
Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study.

Fargion S, Fracanzani AL, Rossini A, Borzio M, Riggio O, Belloni G, Bissoli F, Ceriani R, Ballare M, Massari M, Trischitta C, Fiore P, Orlandi A, Morini L, Mattioli M, Oldani S, Cesana B, Fiorelli G.

Dipartimento Medicina Interna, Ospedale Maggiore IRCCS, Universita di Milano, Italy.

OBJECTIVES: It has been suggested that iron depletion improves the response to interferon in patients with chronic hepatitis C. We aimed to evaluate whether iron reduction by phlebotomy before interferon improves the rate of virological sustained response in previously untreated noncirrhotic patients. METHODS: One hundred fourteen hepatitis C virus (HCV) RNA positive patients with hepatic iron concentrations of > or =700 microg/g dry wt (men) and > or =500 microg/g dry wt (women), stratified according to HCV genotype and gamma-glutamyltransferase values, were randomly allocated to interferon alone (6 MU three times a week) (group A) or to phlebotomy until iron depletion followed by interferon (6 MU three times a week) (group B). After 4 months dosage was reduced to 3 MU three times a week for another 8 months. RESULTS: Virological sustained response was observed in 25 patients (22%), nine (15.8%, 95% CI = 7.5-27.9) of group A and 16 (28.1%, 95% CI = 17.0-41.6) of group B. At univariate analysis the variables associated with the response were HCV genotypes 2-3, normal gamma-glutamyltransferase, higher levels of baseline ALT, normal ALT values, and negativity for HCV-RNA at the 3rd month of therapy. At multivariate analysis, genotype and ALT levels at enrollment maintained their association with the response. A trend toward a better response to interferon was observed in patients who received phlebotomy (odds ratio = 2.32, 95% CI = 0.96-6.24, p = 0.082). Patients with hepatic iron concentration of < or = 1100 microg/g dry wt had a trend toward a higher rate of virological sustained response (p = 0.059) when submitted to treatment B. CONCLUSION: Iron removal by phlebotomy is able to improve the rate of response to interferon, especially in patients with lower hepatic iron deposits ; it could be useful as adjuvant therapy to new therapeutic modalities.

Âîïðîñ, î êàêîì «iron depletion» èäåò ðå÷ü? Õîòÿ êîíöåíòðàöèè ñûâîðîòî÷íîãî è äåïîíèðîâàííîãî â ïå÷åíè, ñåëåçåíêå æåëåçà âçàèìîñâÿçàíû, íà ñîäåðæàíèå êàêîãî æåëåçà, â ïåðâóþ î÷åðåäü, ìîæåò âëèÿòü êðîâîïóñêàíèå? È, íàêîíåö, ãëàâíîå: íåñêîëüêî ïàðàäîêñàëüíûé âûâîä, èç-çà êîòîðîãî ÿ îáðàòèë âíèìàíèå íà ýòó ðàáîòó: especially in patients with lower hepatic iron deposits (îñîáåííî ó ïàöèåíòîâ ñ áîëåå íèçêèì ñîäåðæàíèåì æåëåçà â ïå÷åíè).

P.S. Åñëè ïîçâîëèòå, åù¸ îäèí âîïðîñ. Ñîäåðæàíèå æåëåçà íåìàëîâàæíûé, íî âñå æå îäèí èç ìíîãèõ è ìíîãèõ ïîêàçàòåëåé ãîìåîñòàçà. Âàì õîðîøî èçâåñòíî, ÷òî äàæå äëèòåëüíûé, íî íå î÷åíü ãëóáîêèé æåëåçîäåôèöèò ñîâñåì íå îáÿçàòåëüíî ïðèâîäèò ê àíåìèè, îðãàíèçì îáëàäàåò íåñêîëüêèìè óðîâíÿìè àäàïòàöèîííûõ âîçìîæíîñòåé ê ðàçëè÷íûì äåôèöèòàì. Äëÿ ðàçâèòèÿ àíåìèè, êàê ïðàâèëî, íåîáõîäèìî íàëè÷èå è íåêîòîðûõ äðóãèõ íåáëàãîïðèÿòíûõ ôàêòîðîâ. Ïî÷åìó âñå æå, ïðè äèàãíîñòèêå ñîâåðøåííî ðàçíûõ çàáîëåâàíèé, Âû íåðåäêî ðåêîìåíäóåòå, â ïåðâóþ î÷åðåäü, îáðàùàòü âíèìàíèå íà ñîäåðæàíèå æåëåçà?
Ñ óâàæåíèåì.
Îòâåòèòü ñ öèòèðîâàíèåì
  #26  
Ñòàðûé 19.11.2003, 08:32
Àâàòàð äëÿ YuriTop
YuriTop YuriTop âíå ôîðóìà
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.12.2002
Ãîðîä: Yekaterinburg
Ñîîáùåíèé: 808
YuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåYuriTop ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Áëàãîäàðþ ã-íà Çàéöåâà è Dr.Vad çà âàæíûå ññûëêè è çàìå÷àíèÿ.
Îòâåò AlexT -âûäåëåíèå CMV ìåòîäîì PCR ïðîâîäèëîñü â ñîñêîáå ñ öåðâèêàëüíîãî êàíàëà è ñûâîðîòêå êðîâè.

Ïîäûòîæèâàÿ äàííóþ äèñêóññèþ, õî÷ó åùå ðàç ñêàçàòü, ÷òî ÿ íå ïðîòèâ èñïîëüçîâàíèÿ ïðåïàðàòîâ æåëåçà äëÿ êîðððåêöèè äàííîãî ñîñòîÿíèÿ. Ïðîñòî ïðè èõ íàçíà÷åíèè íóæíî ó÷èòûâàòü âåñü ñïåêòð ôàêòîðîâ âëèÿþùèõ íà ñîñòîÿíèå ïàöèåíòà.
Îòâåòèòü ñ öèòèðîâàíèåì
  #27  
Ñòàðûé 19.11.2003, 13:51
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad íà ôîðóìå
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,855
Ïîáëàãîäàðèëè 33,441 ðàç(à) çà 31,784 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Â. Çàéöåâ!

Íà ñàìîì äåëå, êàê Âû âèäèòå, ìíîãî æåëåçà êàê è ìàëî æåëåçà â îðãàíèçìå - ýòî ïëîõî.

Ðóññêèé ïåðåâîä äàííîé ñòàòüè òåçèñîâ íå ñîâñåì ñîîòâåòñòâóåò àíãëèéñêîìó îðèãèíàëó.

Ïîïðîáóþ îòâåòèòü íà Âàøè âîïðîñû: â ýòîì ñëó÷àå, äà è â íåêîòîðûõ äðóãèõ, êðîâîïóñêàíèå íàïðàâëåíî íà óäàëåíèå èçáûòêà æåëåçà, ñâåðõ íîðìû íàêàïëèâàþùåãîñÿ â òêàíÿõ (ïðè ýðèòðåìèè/íåêîòîðûõ ýðèòîöèòîçàõ âûïóñê êðîâè íàïðàâëåí íà ñíèæåíèå ãåìàòîêðèòà). Ïðîöåññ èäåò ñëåäóþùèì îáðàçîì - ïîÿâëÿþùàÿñÿ ïîñòãåìîððàãè÷åñêàÿ àíåìèÿ ñòèìóëèðóåò ýðèòðîïîýç è ñèíòåç ãåìîãëîáèíà èäåò èç æåëåçà, äåïîíèðîâàííîãî â ðàçëè÷íûõ òêàíÿõ (ãëàâíûì îáðàçîì èç êîñòíîãî ìîçãà è ïå÷åíè), íî òàêæå è èç äðóãèõ ìåñò. Åñëè ïîñìîòðåòü âíèìàòåëüíî íà èìåþùèåñÿ ðåëåâàíòíûå ñòàòüè, òî âèäèì, ÷òî êðîâîïóñêàíèå (óäàëåíèå èçáûòêà æåëåçà) ñíèæàåò ÷àñòîòó ïîäàãðè÷åñêèõ àòòàê, ïîâûøàåò ÷óâñòâèòåëüíîñòü ê èíñóëèíó, óëó÷øàåò ëèïèäíûå ïîêàçàòåëè, îñîáåííîå óëó÷øåíèå ó ïàöèåíòîâ ñ âûñîêèì ôåððèòèíîì (ñóððîãàòíûé ïîêàçàòåëü çàïàñîâ æåëåçà â îðãàíèçìå).

Öèòàòà: "È, íàêîíåö, ãëàâíîå: íåñêîëüêî ïàðàäîêñàëüíûé âûâîä, èç-çà êîòîðîãî ÿ îáðàòèë âíèìàíèå íà ýòó ðàáîòó: especially in patients with lower hepatic iron deposits (îñîáåííî ó ïàöèåíòîâ ñ áîëåå íèçêèì ñîäåðæàíèåì æåëåçà â ïå÷åíè)."

Ïàðàäîêñà çäåñü íåò - ïîçâîëüòå îáüÿñíèòü: ýôôåêòèâíîñòü îò ëå÷åíèÿ çàâèñèò îò ñîäåðæàíèÿ æåëåçà â ïå÷åíè; ïî÷åìó ÷àñòü ñ êðîâîïóñêàíèåì óëó÷øåíèå, íî íå ó âñåõ? ïîòîìó, ÷òî ó ÷àñòè ïàöèåíòîâ (æåíùèí äî ìåíîïàóçû, íàïð. çàïàñû æåëåçà â ïå÷åíè íå âåëèêè) êðîâîïóñêàíèå íå ñíèçèëî íèæå êðèòè÷åñêîãî óðîâíÿ ñîäåðæàíèå æåëåçà â ïå÷åíè, ó äðóãèõ (íàïð. ó ïàöèåíòîâ ñ î÷åíü âûñîêèì ñîäåðæàíèåì) - íå óäàëîñü ïîíèçèòü (ìîæåò íóæíî áûëî áîëüøå ñåàíñîâ êðîâîïóñêàíèé). Ïîñìîòðèòå, âåäü ïàöèåíòû áûëè ñ ïå÷åíî÷íûì æåëåçîì áîëåå 500 èëè áîëåå 700, à âåðõíÿÿ ãðàíèöà íå óêàçàíà.

Èìåþòñÿ òàêæå ñòàòüè ïîêàçûâàþùèå, ÷òî ó ìåíñòðóèðóþùèõ æåíùèí âèðóñíûé ãåïàòèò ïðîòåêàåò ëåã÷å, òîëüêî êðîâîïóñêàíèÿ ïðè ãåïàòèòå ñíèæàþò ôåðìåíòåìèþ, ìàðêåðû ôèáðîçèðîâàíèÿ:

Sartori M, Andorno S, Rigamonti C, Grossini E, Nicosia G, Boldorini R.
Chronic hepatitis C is mild in menstruating women.
J Gastroenterol Hepatol. 2000 Dec;15(12):1411-7.


Dig Liver Dis. 2001 Mar;33(2):157-62.
Chronic hepatitis C treated with phlebotomy alone: biochemical and histological outcome.

Sartori M, Andorno S, Rigamonti C, Boldorini R.

...PATIENTS: Twenty-four non-haemochromatotic patients with chronic hepatitis C were treated with long-term phlebotomy alone. RESULTS: Hepatic iron concentration had decreased in all patients who underwent a second liver biopsy, two years after iron depletion was attained and maintained. Histological grading score decreased in four patients, was unchanged in two, and increased in five. Histological staging score decreased in two patients, was unchanged in five, and increased in four. Pretreatment high serum selenium level predicted the reduction of the inflammatory grading score in univariate analysis (p=0.008, while low serum aspartate aminotransferase (p=0.02) and low propeptide of procollagen III (p=0.08) levels predicted the lack of progression of liver fibrosis. Furthermore, when iron depletion was reached, significant reductions of serum levels of aminotransferase, gamma glutamyl transferase (-47%), propeptide of procollagen III, alpha foetoprotein, selenium were observed in 24 patients. No changes in serum hepatitis C virus-RNA levels were found...


Î æåëåçîäåôèöèòå è æåëåçîäåôèöèòíîé àíåìèè: îäèí èç íåìíîãèõ ìåõàíèçìîâ àäàïòàöèè ê æåëåçîäåôèöèòó - ýòî äâóêðàòíîå ïîâûøåíèå âñàñûâàíèÿ æåëåçà ïðè àíåìèçàöèè îðãàíèçìà.

Ïîçâîëüòå ïðîèëëþñòðèðîâàòü ðåàëüíûì ïðèìåðîì èç æèçíè: ìîëîäîé ÷åëîâåê (ìîé ðîäñòâåííèê) ïåðèîäè÷åñêè ïðîñòóæèâàëñÿ, çàáîëåâàíèÿ ïðîâîöèðîâàëèñü ïðèåìîì õîëîäíîãî ïèòüÿ èëè íåáîëüøèì ïåðåîõëàæäåíèåì, äíåâíàÿ ñîíëèâîñòü, ñíèæåíèå ïàìÿòè è êîíöåíòðàöèè âíèìàíèÿ, ïîÿâèëèñü çàòðóäíåíèÿ ãëîòàíèÿ òâåðäîé ñóõîé ïèùè (âñå âðåìÿ çàïèâàë), ñòàëè âûïàäàòü âîëîñû, "âîëíèòüñÿ" íîãòè.  ïåðèîäè÷åñêèõ îáùèõ àíàëèçàõ êðîâè ãåìîãëîáèí 135-140. Íà àâòîìàòå: MCV, MCH íà íèæíåé ãðàíèöå íîðìû, RDW 15%, ñûâ. æåëåçî 12, ÎÆÑÑ 65. Âîçìîæíîñòè îïðåäåëèòü ôåððèòèí íå áûëî. ÈÇ-çà âûñîêîé âåðîÿòíîñòè íàëè÷èÿ æåëåçîäåôèöèòà (êëèí. ïðèçíàêè, ÑÆ/ÎÆÑÑ ìåíåå 20% , í - 30-35%) áûë ïðåäïðèíÿò êóðñ çàìåñòèòåëüíîé òåðàïèè. Êëèíèêà "óøëà", íûíåøíèé ãåìîãëîáèí 150-155.
Íå áóäó âäàâàòüñÿ ïî÷åìó âçÿëñÿ ÆÄ èëè äð. íþàíñû, íî õî÷ó îáðàòèòü âíèìàíèå íà íå÷àñòîå íàáëþäåíèå: ðàçíèöó ìåæäó "íîðìàëüíûì" è "æåëåçîäåôèöèòíûì" ãåìîãëîáèíàìè - âîò èìåííî ýòè 10-15 ã/ë îðãàíèçì è âîñïðèíèìàåò êàê "àíåìèçàöèþ" (íå çàìåòíóþ ñî ñòîðîíû - âåäü âñå öèôðû â ïðåäåëàõ òåõ íîðì: 130-160) è ïîâûøàåò âñàñûâàíèå æåëåçà, ïðåïÿòñòâóþùåå áîëåå ãëóáîêîé àíåìèçàöèè, íî æåëåçî ðàñõîäóåòñÿ ñòðîãî íà âûïîëíåíèå êðèòè÷åñêîé ôóíêöèè - ïîääåðæàíèå ýðèòðîïîýçà.

Çà÷åì ÿ àêöåíòèðóþ âíèìàíèå íà íàðóøåíèå ìåòàáîëèçìà æåëåçà âî ìíîãèõ ñèòóàöèÿõ?

ñàìûå ðàçíîîáðàçíûå êëèíè÷åñêèå ïðîÿâëåíèÿ ìîãóò áûòü èç-çà íàðóøåíèÿ îáìåíà æåëåçà;

âûñîêèé ïðîöåíò âñòðå÷àåìîñòè êàê äåôèöèòà (îò 10 äî 35% â çàâèñèìîñòè îò ãðóïïû), òàê è ïåðåãðóçêè (5-15% ðàñïðîñòðàíåííîñòè ãåíà ãåìîõðîìàòîçà) â ïîïóëÿöèè ëþäåé;

èõ ëåãêî äèàãíîñòèðîâàòü (íèçêèé ôåððèòèí èëè ÑÆ/ÎÆÑÑ ìåíåå 20-25% - äåôèöèò æåëåçà, âûñîêèé ôåððèòèí èëè ÑÆ/ÎÆÑÑ áîëåå 45-50% - èçáûòîê æåëåçà, ãåìîõðîìàòîç);

èõ ëåãêî ëå÷èòü: çàìåñòèòåëüíàÿ òåðàïèÿ èëè êðîâîïóñêàíèå;

è ñàìîå ãëàâíîå, íàâåðíîå, ÿ êîìïåòåíòåí â ýòîì (êàê Âû âî âñåõ îáëàñòÿõ, ñâÿçàííûõ ñ îçîíîòåðàïèåé: îò ïîêàçàíèé äî íþàíñîâ â îçîíî-ïðîäóöèðóþùèõ óñòðîéñòâàõ).
Îòâåòèòü ñ öèòèðîâàíèåì
  #28  
Ñòàðûé 20.11.2003, 02:28
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Óâàæàåìûé Dr.VAD!
ß âåäü è çàäàþ ýòè âîïðîñû, èìåííî ïîòîìó, ÷òî Âû êîìïåòåíòíû, õîðîøî ðàçáèðàåòåñü è íà÷èòàíû â ýòîé îáëàñòè. ß íèêîåì îáðàçîì íå ïîäâåðãàþ ñîìíåíèþ ïðèìåðû, êîòîðûå Âû ïðèâîäèòå íà ôîðóìå, ÷òî æåëåçîäåôèöèò ìîæåò ïðîâîöèðîâàòü èëè óñóãóáëÿòü òå èëè èíûå ïàòîëîãèè. Òåì áîëåå, ÷òî æåëåçî íå òîëüêî ãåìîãëîáèí è ìèîãëîáèí, íî íåîáõîäèìûé ýëåìåíò äëÿ öèòîõðîì, êàòàëàçû, öåëîãî ðÿäà èììóííûõ ôàêòîðîâ è äð.
Íî âåäü, â ïåðâóþ î÷åðåäü, â ïîëèýòèîëîãè÷åñêèõ çàáîëåâàíèÿõ âñå æå èùóò íàèáîëåå ðàñïðîñòðàíåííûå ïðè÷èíû, ò.å. òå, êîòîðûå îïðåäåëÿþò ýòó ïàòîëîãèþ ó áîëüøèíñòâà áîëüíûõ. À æåëåçîäåôèöèò ÿâëÿåòñÿ äîìèíèðóþùèì ýòèîëîãè÷åñêèì ôàêòîðîì äàëåêî íå ó âñåõ çàáîëåâàíèé.
Ïî ïîâîäó àäàïòàöèîííûõ ìåõàíèçìîâ, òî íà îòíîñèòåëüíî êîðîòêèé ïðîìåæóòîê âðåìåíè ñ íèìè çàâÿçàíû ôåððèòèí è ãåìîñèäåðèí, ïðè äëèòåëüíîì äåôèöèòå àäàïòàöèÿ ìîæåò ñîïðîâîæäàòüñÿ îïðåäåëåííîé ïåðåñòðîéêîé ðÿäà ìåòàáîëè÷åñêèõ ïðîöåññîâ, â òîì ÷èñëå, êàê Âû òî÷íî îòìåòèëè, ïîâûøåíèåì âñàñûâàíèÿ æåëåçà.

×òî êàñàåòñÿ, ðàçáèðàåìîé ðàáîòû ñ ãåïàòèòîì, òî íåò ñîìíåíèÿ – îïðåäåëÿþùèì çäåñü ÿâëÿåòñÿ æåëåçî â ïå÷åíè, õîòÿ áû ïîòîìó, ÷òî âèðóñ ðåïðîäóöèðóåòñÿ â ãåïàòîöèòàõ. Íî ÿ îáðàòèë Âàøå âíèìàíèå íà òî, ÷òî íàèáîëüøèé ýôôåêò îò êðîâîïóñêàíèÿ èññëåäîâàòåëè êàê ðàç ïîëó÷èëè íå òîãäà, êîãäà æåëåçà áûëî äåïîíèðîâàíî â ïå÷åíè â èçáûòêå, à ïðè îòíîñèòåëüíî íåáîëüøèõ êîíöåíòðàöèÿõ, ò.å. ïðè ñíèæåíèè êîíöåíòðàöèè æåëåçà â ïå÷åíè äî íèçêèõ êîíöåíòðàöèé, à íå äî íîðìû. Âïîëíå âåðîÿòíî, êàê Âû îòìåòèëè, àíàëîãè÷íûé ýôôåêòà ïðè âûñîêîì íà÷àëüíîì ñîäåðæàíèè æåëåçà â ïå÷åíè ìîã áû ïîëó÷èòü ïðè ïîâòîðíûõ êðîâîïóñêàíèÿõ. Íî, êàê Âû ïîíèìàåòå, òàêèå ìàíèïóëÿöèè èìåþò ñâîè îãðàíè÷åíèÿ: ïðè êðîâîïóñêàíèÿõ òåðÿåòñÿ íå òîëüêî æåëåçî.
Ñ óâàæåíèåì.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 23:25.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.